VivoSeq
Infectious Disease

Hepatitis

184

Pipeline Programs↗

34

Active Trials↗

74

Companies Involved↗

Hepatitis is a highly competitive landscape with 184 programs across 74 companies. The most active players are Oasis Pharmaceuticals, LLC, Eiger BioPharmaceuticals, Bayer. 43 therapies are approved with 33 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

36/100

Mech. Concentration

8/100

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

Oasis Pharmaceuticals, LLC

1 program

Phase 1E

Eiger BioPharmaceuticals

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1A

Adaptive Phage Therapeutics, Inc.

1 program

Phase 1Biogen logo

Biogen

1 program

Phase 1Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Phase 1

Pipeline

Programs by Phase

Preclinical19

Acetaminophen

Kenvue Brands

Hydroxychloroquine

Alnylam Pharmaceuticals

Blood Collection

Assistance Publique - Hôpitaux de Paris

Lopinavir/ritonavir

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Plasma Exchange

Sanofi

Phase 111

Ciprofloxacin

Bayer

Sodium Hyaluronate

Sanofi

Bacteriophage

Adaptive Phage Therapeutics, Inc.

Eyp001a

Enyo Pharma

Ontamalimab

Takeda

Phase 278

Semaglutide

Novo Nordisk

Pemvidutide

Altimmune

Obeticholic Acid

Intercept Pharmaceuticals

Efruxifermin

Akero Therapeutics

SAR440340

Sanofi

Phase 333

Peginterferon Alfa-2b

Merck & Co.

Pioglitazone

Takeda

Coenzyme Q10

Mclean Hospital

Pentoxifylline

Validus Pharmaceuticals

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved43

Immune Globulin

CSL Behring

Telbivudine

Novartis

Tenofovir Disoproxil

Gilead

Lamivudine

Glaxo Dba Glaxosmithkline

Hepatitis a Vaccine

Sanofi

Analysis

Modality Breakdown

79%

Small molecule

149 of 189 classified programs — the dominant modality here.

21%ALL OTHERSVaccine2815%Protein / enzyme42%Peptide42%Monoclonal antibody32%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 189 classified programs, each share of the total. Modality classified for 100% of 238 pipeline programs.

Analysis

Trial Status

243

clinical trials

Completed141 · 58%
Unknown status34 · 14%
Terminated24 · 10%
Recruiting18 · 7%
Withdrawn10 · 4%
Not yet recruiting10 · 4%
Other6 · 2%

Clinical Trials

Trial Activity

243 trials

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
Recruiting·BBausch Health Americas, Inc.·Phase 3·NCT07428538·350 enrolled
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 2·NCT07145151·156 enrolled
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Recruiting·VVA Office of Research and Development·Phase 2·NCT05526144·128 enrolled
Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
Recruiting·UUniversity Hospital, Montpellier·N/A·NCT06470997·60 enrolled
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT06937749·165 enrolled
Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis
Recruiting·NNational Taiwan University Hospital·Phase 3·NCT07265297·210 enrolled
Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
Recruiting·SSentara Norfolk General Hospital·N/A·NCT03886077·50 enrolled
Short Course Steroids in Alcohol Associated Hepatitis
Recruiting·—·Phase 3·NCT06919458·146 enrolled
HA35 Moderate Alcoholic Hepatitis (AH) Study
Recruiting·TThe Cleveland Clinic·Phase 1·NCT05018481·54 enrolled
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Recruiting·—·Phase 2·NCT03383419·15 enrolled
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Recruiting·IIntercept Pharmaceuticals·Phase 2·NCT05639543·80 enrolled
HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
Recruiting·Tasly Pharmaceutical Group Co., Ltd logoTasly Pharmaceutical Group Co., Ltd·Phase 2·NCT05632861·76 enrolled
Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis
Recruiting·MMahidol University·Phase 4·NCT06484530·116 enrolled
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
Recruiting·—·N/A·NCT05294744·390 enrolled
Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids
Recruiting·UUniversity Hospital, Basel, Switzerland·N/A·NCT07167251·63 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)